Sara Salama1, Santiago Pardo2, Michael Levy2. 1. Department of Neurology, University of Alexandria, Alexandria, Egypt; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA. Electronic address: ssalamafouad@gmail.com. 2. Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Abstract
BACKGROUND: Serological antibodies against myelin oligodendrocyte glycoprotein (MOG) are associated with a relapsing autoimmune demyelinating disease of the central nervous system. Initially identified in the context of acute disseminated encephalomyelitis, persistent seropositivity of MOG antibodies is now recognized as a variant of neuromyelitis optica spectrum disorder (NMOSD). OBJECTIVES: The aim of the study is to describe the epidemiological and clinical features of MOG antibody positive cases and compare our findings with those previously published. METHODS: This is a retrospective descriptive study of 23 patients with MOG antibody disease who were cared for at Johns Hopkins Hospital over the period from 2015 to 2018. MOG testing was done at Johns Hopkins using the cell based assay (CBA). We describe their epidemiological and clinical features. RESULTS: Twenty-three patients were included in the study with a female to male ratio of 2.3:1. The mean age of the cohort was 42.6 years, while the mean age at onset was 37 years. The most frequent initial presentation was optic neuritis, followed by ADEM-like encephalopathic clinical picture and transverse myelitis. Five patients showed a monophasic disease course while the rest experienced a relapsing phenotype. Nine patients (39%) experienced immediate relapses on withdrawal of steroids. CONCLUSIONS: Our cohort showed clinical characteristics comparable with previously published reports of MOG antibody disease worldwide. Unique features of MOG antibody disease are: high frequency of optic neuritis attacks, good long term neurological recovery and sensitivity to steroid use and withdrawal.
BACKGROUND: Serological antibodies against myelin oligodendrocyte glycoprotein (MOG) are associated with a relapsing autoimmune demyelinating disease of the central nervous system. Initially identified in the context of acute disseminated encephalomyelitis, persistent seropositivity of MOG antibodies is now recognized as a variant of neuromyelitis optica spectrum disorder (NMOSD). OBJECTIVES: The aim of the study is to describe the epidemiological and clinical features of MOG antibody positive cases and compare our findings with those previously published. METHODS: This is a retrospective descriptive study of 23 patients with MOG antibody disease who were cared for at Johns Hopkins Hospital over the period from 2015 to 2018. MOG testing was done at Johns Hopkins using the cell based assay (CBA). We describe their epidemiological and clinical features. RESULTS: Twenty-three patients were included in the study with a female to male ratio of 2.3:1. The mean age of the cohort was 42.6 years, while the mean age at onset was 37 years. The most frequent initial presentation was optic neuritis, followed by ADEM-like encephalopathic clinical picture and transverse myelitis. Five patients showed a monophasic disease course while the rest experienced a relapsing phenotype. Nine patients (39%) experienced immediate relapses on withdrawal of steroids. CONCLUSIONS: Our cohort showed clinical characteristics comparable with previously published reports of MOG antibody disease worldwide. Unique features of MOG antibody disease are: high frequency of optic neuritis attacks, good long term neurological recovery and sensitivity to steroid use and withdrawal.
Authors: Immy A Ketelslegers; Daniëlle E Van Pelt; Susanne Bryde; Rinze F Neuteboom; Coriene E Catsman-Berrevoets; Dörte Hamann; Rogier Q Hintzen Journal: Mult Scler Date: 2015-02-06 Impact factor: 6.312
Authors: Patrick Waters; Mark Woodhall; Kevin C O'Connor; Markus Reindl; Bethan Lang; Douglas K Sato; Maciej Juryńczyk; George Tackley; Joao Rocha; Toshiyuki Takahashi; Tatsuro Misu; Ichiro Nakashima; Jacqueline Palace; Kazuo Fujihara; M Isabel Leite; Angela Vincent Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-03-19
Authors: Florence Pache; Hanna Zimmermann; Janine Mikolajczak; Sophie Schumacher; Anna Lacheta; Frederike C Oertel; Judith Bellmann-Strobl; Sven Jarius; Brigitte Wildemann; Markus Reindl; Amy Waldman; Kerstin Soelberg; Nasrin Asgari; Marius Ringelstein; Orhan Aktas; Nikolai Gross; Mathias Buttmann; Thomas Ach; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt Journal: J Neuroinflammation Date: 2016-11-01 Impact factor: 8.322
Authors: Maciej Juryńczyk; George Tackley; Yazhuo Kong; Ruth Geraldes; Lucy Matthews; Mark Woodhall; Patrick Waters; Wilhelm Kuker; Matthew Craner; Andrew Weir; Gabriele C DeLuca; Stephane Kremer; Maria Isabel Leite; Angela Vincent; Anu Jacob; Jérôme de Sèze; Jacqueline Palace Journal: J Neurol Neurosurg Psychiatry Date: 2016-10-08 Impact factor: 10.154